Ti sento means “I hear you" in Italian.

At Tisento Therapeutics, we believe that meaningful innovation requires understanding the problem, and that starts with listening. First and foremost, we listen to those impacted by debilitating diseases to understand the daily challenges they face. We also listen to healthcare providers, patient advocates, regulatory agencies, and scientific data. All these inputs inform our thinking and shape how we conduct our research, design our trials, and evolve our company. We are on a mission to deliver medicines that address what matters most.

Our lead candidate is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator, which is advancing in MELAS and other genetic mitochondrial diseases. Zagociguat is ideally suited to treat mitochondrial diseases with both CNS and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness.

Biotechnology

Health Care

Life Sciences

Pharmaceutical

Therapeutics

Tisento Therapeutics

Peter Hecht

Marta Cavero Tomas

Jennifer Chickering

Sara Hagmeier

G. Todd Milne

Bill Kissel

Tisento Therapeutics

Org chart

Similar companies